Geron good article by Ivan Deryigin

I could have sold my shares in September and walked away with profits of almost 70%, and that would have been the end of it. However, I chose not to do that. And the reason is simple. This was, and is, an investment only for risk tolerant investors, who have room for speculation in their portfolios. And I consider this investment to be, at the moment, a speculative one. When I wrote my original article, I stated that Geron has the potential to change the way that cancer is treated, due to its focus on telomerase inhibition and brain tumors. I stand by that opinion. The failure of imetelstat in solid tumors has not affected the company`s hematologic trials, nor has it affected the development of GRN-1005, which has the potential to create a truly effective treatment for brain metastases, something that has eluded cancer researchers and pharmaceutical companies for years, due to the blood-brain barrier and the difficulty of getting cancer medications across it. While Geron does have the potential to change the way that cancer is treated, the path ahead is an uncertain one, and this stock is not meant for all investors. But, for investors who are willing to take the risk, Geron continues to offer the opportunity for profits, with the next catalyst just a month away. Above is a small part of the article. This is the guy who pumped it up in Sept. up to $2.99. I hope he can do it again. With good results we should go to $3, with poor results it's all over. Geron is up 7 cents on this article. Good luck in this rigged casino,